在blinatumomab治疗期间感染新型冠状病毒肺炎：安全性是一个两难问题吗？
COVID-19 infection during blinatumomab therapy: Is safety a dilemma?
作者信息
Barahona-Correa Julián E, Rueda-Ortiz Camilo, López María-José, Gualtero Sandra, Arevalo-Zambrano Mónica
机构信息
Department of Internal Medicine, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogota, Colombia.
Division of Infectious Diseases, Hospital Universitario San Ignacio, Bogota, Colombia.
出版信息
SAGE Open Med Case Rep. 2023 Jan 10;11:2050313X221148548. doi: 10.1177/2050313X221148548. eCollection 2023.
Patients with acute lymphoblastic leukemia may be particularly vulnerable to SARS-CoV-2 infection and severe illness. The mainstay of current treatment is the use of blinatumomab in patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia. We discuss the case of a patient with relapsed acute lymphoblastic leukemia who became positive for SARS-CoV-2 during blinatumomab therapy. There are no formal recommendations on the decision to continue, withhold, or delay blinatumomab treatment in these patients. More studies exploring this issue are warranted, as SARS-CoV-2 is expected to be here to stay.
急性淋巴细胞白血病患者可能特别容易感染新型冠状病毒并患上重症。目前治疗的主要方法是在难治性或复发性B细胞前体急性淋巴细胞白血病患者中使用博纳吐单抗。我们讨论了一例复发性急性淋巴细胞白血病患者在接受博纳吐单抗治疗期间新型冠状病毒检测呈阳性的病例。对于这些患者，在决定继续、停用或延迟博纳吐单抗治疗方面尚无正式建议。鉴于预计新型冠状病毒将长期存在，有必要开展更多研究来探讨这个问题。
Zotero 插件